Tattooing is a more effective way of administering DNA vaccines than direct injection

Tattooing is a more effective way of administering DNA vaccines than direct injection into muscle tissue, according to new research by German and Czech scientists. In DNA vaccination, a gene from a pathogen is injected directly into the host, which then produces the corresponding pathogen protein inside its own cells. This triggers a response from the host's immune system. Advantages of DNA vaccination include the fact that the vectors can be constructed quickly, and rapid and large scale vaccine production is much cheaper than for traditional vaccines. These vaccines are also temperature stable; in contrast many traditional vaccines require cold storage and have a limited lifetime.

In this latest piece of research, the scientists compared tattoo delivery with intramuscular injection, both with and without the use of additional adjuvants, which are designed to boost the immune response of the vaccine. Their results are published in the journal Genetic Vaccines and Therapy.

The tattoo method gave a much stronger antibody and cellular response than intramuscular injection. Three doses of DNA vaccine delivered via tattooing elicited antibody levels 16 times higher than three intramuscular injections with adjuvant. The scientists also found that while adjuvants boosted the immune response for intramuscular vaccinations, they had no effect on DNA vaccinations.

The process of tattooing causes a wound and sufficient inflammation to 'prime' the immune system. Furthermore, it covers a larger area of the skin than an injection, allowing the DNA vaccine to get into more cells. The researchers speculate that these factors could contribute to the efficacy of tattooing as a vaccine delivery method.

"Vaccination with naked DNA has been hampered by its low efficiency," commented Martin Müller of the German Cancer Research Centre (DKFZ), who led the research. "Delivery of DNA via tattooing could be a way for a more widespread commercial application of DNA vaccines."

While acknowledging that tattooing may not be acceptable for everyone - the procedure is rather painful - the scientists believe it could have applications for the routine vaccine of livestock, or for delivering therapeutic (as opposed to preventive) vaccines in people. "Nevertheless, DNA vaccination via tattoo seems to be the method of choice if faster and stronger immune responses have to be achieved," the researchers conclude.

Advantages of the tattoo method include the low cost of the tattooing device and a standardised method for the application. On the down side, the researchers cite the strain on the animals and a 'somewhat cumbersome application procedure'.

Tattooing is already in use in some medical research applications where it is used to deliver materials to the skin, for example for scar treatments. It is also used to study the processes involved in cosmetic tattooing, or to deliver DNA for prospective gene therapy of skin disorders.

For more information, please visit:
http://www.gvt-journal.com/content/6/1/4

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...